Biogen to acquire Reata for $7.3 billion in cash

Biogen Inc. will purchase Reata Pharmaceuticals Inc. for $7.3 billion in cash, with the transaction expected to close in the fourth quarter of 2023, the Massachusetts-based company announced on Friday…